Century Therapeutics, Inc. (NASDAQ:IPSC) Stock Rated “Hold” by Wall Street Brokerages

Century Therapeutics, Inc. (NASDAQ:IPSC) has been given a consensus rating of “Hold” by the seven ratings firms that are currently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $4.75.

Several brokerages have commented on IPSC. Wall Street Zen upgraded shares of Century Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, September 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Century Therapeutics in a research note on Thursday, July 2nd.

Century Therapeutics Stock Performance

Shares of NASDAQ IPSC opened at $1.69 on Friday. Century Therapeutics has a 1 year low of $0.43 and a 1 year high of $3.04. The firm has a market cap of $306.01 million, a P/E ratio of -1.82 and a beta of 1.59. The stock has a fifty day moving average price of $2.02 and a two-hundred day moving average price of $2.20.

Century Therapeutics (NASDAQ:IPSC) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.06). On average, research analysts predict that Century Therapeutics will post -0.51 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Versant Venture Management LLC bought a new stake in shares of Century Therapeutics during the 1st quarter worth $27,495,000. Commodore Capital LP acquired a new stake in Century Therapeutics during the 1st quarter worth about $19,652,000. BlackRock Inc. purchased a new stake in Century Therapeutics during the second quarter valued at about $19,825,000. Seven Fleet Capital Management LP purchased a new stake in Century Therapeutics during the second quarter valued at about $10,652,174. Finally, Trails Edge Capital Partners LP acquired a new position in shares of Century Therapeutics in the second quarter worth about $10,130,674. Institutional investors and hedge funds own 50.20% of the company’s stock.

Century Therapeutics Company Profile

Century Therapeutics, Inc is a biotechnology company focused on developing allogeneic cell therapies for cancer and other serious diseases. The company uses induced pluripotent stem cell (iPSC) technology, gene editing and cell-engineering methods to create potentially off-the-shelf immune cell therapies designed to recognize and eliminate diseased cells.

Its pipeline has included engineered natural killer (NK) cell and T-cell programs targeting blood cancers. Among its leading programs is CNTY-101, an allogeneic CAR NK cell therapy directed at CD19, a target associated with certain B-cell malignancies.